PREVALENCE OF WHITE COAT EFFECT IN TREATED HYPERTENSIVE PATIENTS FROM CARAS SEVERIN COUNTY
|
|
- Cornelius Clark
- 6 years ago
- Views:
Transcription
1 ORIGINAL ARTICLES PREVALENCE OF WHITE COAT EFFECT IN TREATED HYPERTENSIVE PATIENTS FROM CARAS SEVERIN COUNTY Ecaterina Usurel 1, Sorin Pescariu 2,3, Daniel Brie 2, Constantin Erimescu 2, Stefan I. Dragulescu 2,3 REZUMAT Obiectiv: Scopul studiului nostru a fost determinarea incidentei efectului de halat alb pe un lot de pacienti hipertensivi din judetul Caras Severin, a caror hipertensiune arteriala nu este controlata in ciuda tratamentului medicamentos administrat si determinarea incidentei evenimentelor cardiovasculare la acest grup de pacienti, dupa o perioada de urmarire de 48±6 luni. Material si metode: Studiul a inclus 469 de pacienti hipertensivi tratati cu unul sau mai multe medicamente antihipertensive care locuiesc in judeteul Caras Severin, dintre care numai 292 au intrunit criteriile de includere. Rezultate: Dintre cei 292 de pacienti inclusi efectul de halat alb a fost intalnit la 88 de pacienti (30,1%). Incidenta efectului de halat alb a fost mai mare la femei si la fumatori. Pe perioada urmaririi 27 de pacienti au prezentat evenimente cardiovasculare majore (11p cu accident vascular cerebral, 8p cu infact miocardic sau angina pectorala, 5p urgente hipertensive, 3p cu decompensarea fenomenelor de insuficienta cardiaca). Incidenta crescuta a evenimentelor cardiovasculare a fost asociata cu varsta avansata, sexul masculuin, fumatul, nivelul crescut al colesterolului seric si cu valorile crescute ale tensiunii arteriale la monitorizarea ambulatorie. Concluzii: In urma studiului consideram ca la pacientii hipertensivi care prezinta valori crescute ale tensiunii arteriale in ciuda tratamentului medicamentos administrat trebuie luata in considerare monitorizarea ambulatorie/24 h avand in vedere ca efectul de halat alb nu poate fi prezis cu acuratete. Nu a putut fi stabilita o asociere intre efectul de halat alb si incidenta evenimentelor cariovasculare la pacientii urmariti. Cuvinte cheie: efectul de halat alb, judetul Caras Severin, monitorizarea ambulatorie a tensiunii arteriale 24 h, rata evenimetelor cardiovasculare ABSTRACT Objective: The objective of our study was to determine the prevalence of white-coat effect (i.e., difference between clinic and ambulatory blood pressure, or a normal ambulatory blood pressure) in a population of hypertensive patient with treated hypertension from Caras Severin county, a region in Romania, whose clinic blood pressure remained uncontrolled despite therapy and the incidence of cardiovascular events in this group for a period of follow-up 48± 6 month. Material and methods: We included in our study 469 patients with treated essential hypertension, with one or more antihypertensive medications, who live in Caras Severin County, a region from Romania. They must have two or more clinic blood pressure readings of at least 140/90 mm Hg (either/or), 1 month apart but no greater than 200/120 mm Hg (either/or), were 18 years of age or more and had no target organ damage or left ventricular hypertrophy, as evidenced by echocardiography. Only 292 patients met the inclusion criteria. Results: 292 patients (100 men and 192 women; mean age, 55±12 years), all white, who met the inclusion criteria, were included in the study, from whom 88 patients (30.1%) had white coat response. The median duration of follow-up was 48±6 months. The incidence of white coat effect group was great in women (p<0.001) and in smokers (p<0.001) patients. During the follow-up, 27 patients had cardiovascular event (11 with stroke, 8 with coronary heart disease, myocardial infarction, or angina pectoris; 3 with progressive heart failure; 5 with hypertensive emergency). The higher incidence of cardiovascular events was associated with older age, male sex, current smoking, high cholesterol level and higher value on ambulatory blood pressure measurement. The incidence of cardiovascular events in group of patients with white coat effect was low. Conclusion: We consider that patients whose blood pressure remains high despite adequate antihypertensive therapy should be considered for 24-hour ambulatory blood pressure monitoring because a white-coat effect cannot be predicted reliably. The prevalence of white-coat effect is greater in female sex and in smokers. The rate of cardiovascular events over an observation period of 48±6 months did not show any association with the white coat effect. Key Words: white-coat effect, Caras Severin county, 24-hour ambulatory blood pressure monitoring, rate of cardiovascular events 1 County Hospital Resita, 2 Institute of Cardiovascular Medicine, Timisoara, 3 Victor Babes University of Medicine and Pharmacy, Timisoara Correspondence to: Ecaterina Usurel, Spitalul Judetean Resita, Stationar 2, Tel ecaterina.usurel@yahoo.com Received for publication: Jul. 06, Revised: Oct. 28, INTRODUCTION The measurement of blood pressure (BP) in the physician s office may trigger an alerting reaction and a rise in BP. 1 In a study, Mancia et al have shown that the rise in intra-arterial BP during the visit is, on average, 27/14 mm Hg; it is maximal during the first 4 minutes of the visit, disappears within 10 minutes, and persists over several visits. 2,3 The transient rise in BP from Ecaterina Usurel et al 263
2 before to during the visit is usually defined as whitecoat effect or white-coat phenomenon, whereas the coexistence of persistently high office BP with normal ambulatory blood pressure measurement (ABPM), regardless of the extent of the white-coat effect, is often referred to as white coat hypertension (WCH). WCH, which is also referred to as office hypertension or isolated clinic hypertension is generally defined as a persistently elevated office BP in the presence of a normal BP outside the office. 4,5 From a practical standpoint, it is worth noting that the whitecoat effect is a measure of BP change from before to during the visit, whereas white coat hypertension is an operative definition of clinically hypertensive subjects at a low potential risk because of apparently normal mean BP levels during daily life. 2,3,6 A reliable estimate of the white-coat effect may be carried out through intra-arterial or noninvasive techniques, with beat-bybeat measurement of the BP rise from immediately before to during the visit. 2,3,7 White coat hypertension is a common finding in hypertensive populations and in the population at large. The incidence has variably been recorded between 12% and 50%, depending on definitions. 5 The importance of the condition lies in the relatively benign cardiovascular risk with which it is associated compared with established hypertension. 8 The phenomenon of white coat effect or hypertension may reflect an abnormally vigorous sympathetic response to the environment of the measurement, especially the presence of the measuring nurse or physician. 3,9 A document issued by the American Society of Hypertension had defined normalcy of ABP (i.e., average daytime BP <135 mm Hg systolic and <85 mm Hg diastolic). 10 These values correspond to an office BP of 140/90 mm Hg. Depending on the upper limit set for mean daytime ambulatory blood pressure, the prevalence of white-coat response can range from 18% to 60% in populations with untreated hypertension. 11 Most studies of white-coat response have been conducted in subjects with normal blood pressure and those with borderline hypertension who were not receiving drug treatment. Recently, however, Myers and Reeves have found that 70% to 73% of treated patients showed a white-coat response, and 31% to 32% exhibited a marked white-coat effect. 12,13 Thus, white-coat response remains a consideration even among patients with treated hypertension. The objective of our study was to determine the prevalence of white-coat effect (i.e., difference between clinic and ambulatory blood pressure, or a normal ambulatory blood pressure) in a population of hypertensive patient in our area, with treated hypertension whose clinic blood pressure remained uncontrolled despite therapy and the incidence of cardiovascular events in this group for a period of follow-up 48 ± 6 months. MATERIAL AND METHODS We have conducted our study in Caras Severin County, a small region in Romania, after having been approved by the Ethics Committee of University of Medicine and Pharmacy Victor Babes, Timisoara. All patients gave written informed consent. All decisions concerning the study design, the collection, analysis, and interpretation of the data, and the intellectual content of the manuscript were made independently, without the involvement of the pharmaceutical industry sponsors. We included in our study 469 patients with treated essential hypertension, with one or more antihypertensive treatment. They must have had two or more clinic blood pressure readings of at least 140/90 mm Hg (either/or), one month apart, but no greater than 200/120 mm Hg (either/or), were 18 years of age or more and had no target organ damage or left ventricular hypertrophy, as evidenced by echocardiography. Criteria for exclusion were: suspicion of secondary hypertension, recent acute myocardial infarction, recent stroke (occurring within the previous three months), recent hospitalization for chronic heart failure, recent revascularization or planned cardiovascular intervention during the succeeding three months, chronic obstructive pulmonary disease, any coexisting diseases that might seriously reduce life expectancy, pregnancy, and no cooperation to undergo repeated ambulatory blood-pressure monitoring. Only 292 patients meet the inclusion criteria. All patients had a complete clinical workup at the beginning of the study to rule out secondary hypertension and to assess the presence of end-organ damage. Information about traditional cardiovascular risk factors, history of cardiovascular events, current medications, demographic and anthropometric data were collected. At that time, a sample of venous blood was drawn to assess baseline factors and routine 12- lead electrocardiogram was obtained. BP was measured with a mercury sphygmomanometer in a quiet environment, with the patient in a sitting position after 5 minutes of rest, following the recommendations of the British Hypertension Society. 14 Systolic BP (SBP) and diastolic BP (DBP) (Korotkoff phase I and phase V, respectively) represented in each visit the mean of three different readings measured at 5-minute intervals. ABPM was performed with the use of an oscillometric monitor 264 TMJ 2010, Vol. 59, No. 3-4
3 on a regular working day, during the normal intake of the usual antihypertensive treatment. Following the standard protocol, readings at intervals of 30 minutes between 08:00 and 20:00 and at intervals of 60 minutes between 20:00 and 08:00. Daytime ambulatory blood pressure was defined as that between 08:00 and 20:00, and nighttime ambulatory blood pressure as that between midnight and 06:00. The average of SBP, DBP, and mean blood pressure were calculated for every one of the periods. Before starting the study, reliability of BP values measured with the monitor were checked against simultaneous measurements with a mercury sphygmomanometer. Differences of < 5 mm Hg were allowed. Those patients with recordings showing an error rate in > 25% of the total readings were excluded from the study. Subjects were identified as exhibiting white-coat response if their mean daytime ambulatory systolic/ diastolic blood pressure was 139/89 mm Hg (both) or lower, or if the systolic/diastolic pressure was at least 20/15 mm Hg (both) lowers than the clinic reading. All other subjects were considered to have sustained hypertension. Statistical analysis For each variable, values are expressed as mean±sd. Differences between groups were sought 2 by using t test and for discontinuous variables. Event rates for new cardiovascular events, fatal plus nonfatal, during the time of follow-up are presented as the number of events per 100 patient-years, based on the ratio of the observed number of events to the total number of patient-years of exposure. A p value of less than 0.05 was considered significant for all analyses. RESULTS 292 patients (100 men and 192 women; mean age, 55 ± 12 years), all white, who met the inclusion criteria, were included in the study, from whom 88 patients (30.1%) had white coat response. The median duration of follow-up was 48 ± 6 months. Characteristics of the patients according to category of white coat response or sustained hypertension are summarized in Table 1. Eighty-eight patients (30.1%) with treated hypertension from our subjects had white coat effect. The incidence of patients with effect group was greater in women (p<0.001) and in smokers (p<0.001) patients. During the follow-up, 27 patients had a cardiovascular event (11 with stroke, eight with coronary heart disease, myocardial infarction, or angina pectoris; three with progressive heart failure; five with hypertensive emergency). (Table 2) The higher incidence of cardiovascular events was associated with older age, male sex, current smoking, high cholesterol level and higher value on ambulatory blood pressure measurement. The incidence of cardiovascular events in the group of patients with white coat effect was lower than in those with sustained hypertension (p<0.001). Table 1. Baseline characteristics of participants. Characteristics Risk factor White coat effect (n=88) Sustatined hypertension (n=204) Age (yr) 53±10 yr 56±9yr NS Female sex 62/88 (70.5%) 100/204 (49.01%) P value <0.001 Body mass index 30 ± 5 29 ± 4 p=0.14 Current smoking (%) Total serum cholesterol concentration (mg/dl) Office BP (mm Hg) 68% 40% < ± ± 8 p=0.24 Systolic 150 ± ± 9 NS Diastolic 92 ± 4 93 ± 5 NS ABPM 24 H systolic 126 ± ± 8 < H diastolic 82 ± 8 93 ± 7 <0.001 Daytime systolic 128 ± ± 8 <0.001 Daytime diastolic 84 ± 3 95 ± 5 <0.001 Nighttime systolic Nighttime diastolic 118 ± ± 6 < ± 7 84 ± 6 <0.001 Values are means ± SD; the body-mass index is the weight in kilogram divided by square of height in meters. Ecaterina Usurel et al 265
4 Table 2. Cardiovascular events developed during the follow-up period. Cardiovascular events group C (n=26) White coat effect (n=88) Stroke 0 11 Coronary heart disease 1 7 Progression of cardiac failure 1 2 Hypertensive emergency 0 5 Sustained hypetension (n=204) Total events 2 (2.27%) 25 (12.57%) p <0.001 DISCUSSION The white coat effect and white coat hypertension differ in their definitions, pathophysiological mechanisms, and clinical significance. White coat effect is defined as of BP change from before to during the visit. 2,3 White coat hypertension is an attempt to define a low-risk stratum of clinically hypertensive subjects with normal BP levels out of the medical setting, regardless of their rise in BP from before to during the visit. 5,6 A white coat effect was found in total of 36% of our subjects, whose clinic blood pressure remained high, despite antihypertensives. Other investigators have reported prevalence rates of white-coat response of 21% to 73%. 12,13,15,16 The variable definitions of white coat effect may be the explanation of this wide range of value. Several studies have suggested that white-coat hypertension is benign and that antihypertensive therapy is not required, whereas other studies have suggested that it may not be innocent In our study, the white coat effect was found to be associated with low incidences of cardiovascular events in our study population. In a study, Myers and Reeves found a significant difference in the prevalence of the response between women and men. 13 However, other studies have not demonstrated any difference in prevalence among men and women. 16 In our study, women were associated more than man with white coat effect. Several investigators have been used psychological testing, mental stress testing, exercise testing, or examination of levels of anger, anxiety or depression to test for blood pressure variances between patients with a white-coat response and those with sustained hypertension We did not use such a test in our study. The rate of cardiovascular events over an observation period of 48 ± 6 months did not show any association with the white coat effect. CONCLUSION We consider that patients whose blood pressure remains high despite adequate antihypertensive therapy should be considered for 24-hour ambulatory blood pressure monitoring because a white-coat effect cannot be predicted reliably. The prevalence of whitecoat effect is greater in female sex and in smokers. The rate of cardiovascular events over an observation period of 48±6 months did not show any association with the white coat effect. REFERENCES 1. Ayman D, Goldshine AD. Blood pressure determinations by patients with essential hypertension: the difference between clinic and home readings before treatment. Am J Med Sci 1940;200: Mancia G, Bertineri G, Grassi G, et al. Effects of blood pressure measured by the doctor on patient s blood pressure and heart rate. Lancet 1983;2: Mancia G, Parati G, Pomidossi G, et al. Alerting reaction and rise in blood pressure during measurement by physician and nurse. Hypertension. 1987;9: Guidelines Subcommittee. World Health Organization International Society of Hypertension guidelines for the management of hypertension. J Hypertens. 1999;17: Pickering TG, James GD, Boddie C, et al. How common is white-coat hypertension? JAMA 1988;259: Pickering TG. White-coat hypertension in a changing era of medical care. Blood Press Monit 1996;1(Suppl 2):S27-S Parati G, Ulian L, Santucciu C, et al. The difference between clinic and daytime blood pressure is not a measure of the white-coat effect. Hypertension. 1998;31: Verdecchia P, Schillaci G, Borgioni C, et al. White coat hypertension and white coat effect: similarities and differences. Am J Hypertens. 1995;8: Middeke M, Lemmer B. Office Hypertension: abnormal blood pressure regulation and increased sympathetic activity compared with normotension. Blood Pressure Monitoring 1996;1: Pickering T, for an American Society of Hypertension Ad Hoc Panel. Recommendations for the use of home (self) and ambulatory blood pressure monitoring. Am J Hypertens 1996;9: Verdecchia P, Schillaci G, Boldrini F, et al. Variability between current definitions of normal ambulatory blood pressure: implications in the assessment of white coat hypertension. Hypertension 1992;20: Myers MG, Reeves RA. White coat phenomenon in patients receiving antihypertensive therapy. Am J Hypertens 1991;4: Myers MG, Reeves RA. White coat effect in treated hypertensive patients: sex differences. J Hum Hypertens1995;9: Petrie JC, O Brien ET, Littler WA, de Swiet M. British Hypertension Society. Recommendations on blood pressure measurement. BMJ 1986;293: Pierdomenico SD, Mezzetti A, Lapenna D, et al. White coat hypertension in patients with newly diagnosed hypertension: evaluation of prevalence by ambulatory monitoring and impact on cost of health care. Eur Heart J 1995;16: Pierdomenico SD, Lapenna D, Guglielmi MD, et al. Target organ status and serum lipids in patients with white coat hypertension. Hypertension 1995;26: Cavallini MC, Roman MJ, Pickering TG, et al. Is white coat hypertension associated with arterial disease or left ventricular hypertrophy? Hypertension 1995;26: TMJ 2010, Vol. 59, No. 3-4
5 18. Gosse P, Promax H, Durandet P, Clementy J. White coat hypertension: no harm for the heart. Hypertension 1993;22: Bidlingmeyer I, Burnier M, Bidlingmeyer M, et al. Isolated office hypertension: a prehypertensive state. J Hypertens 1996;14: Kuwajima I, Suzuki Y, Fujisawa A, Kuramoto K. Is white coat hypertension innocent? Structure and function of the heart in the elderly. Hypertension 1993;22: Cerasola G, Cottone S, Nardi E, et al. White-coat hypertension and cardiovascular risk. J Cardiovasc Risk 1995;2: Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic significance of the white coat effect. Hypertension 1997;29: Lerman CE, Brody CS, Hui T, et al. The white-coat hypertension response: prevalence and predictors. J Gen Intern Med 1989;4: Siegel WC, Blumenthal JA, Divine GW. Physiological, psychological, and behavioral factors and white coat hypertension. Hypertension 1990;16: Schneider RH, Egan BM, Johnson EH, et al. Anger and anxiety in borderline hypertension. Psychosom Med 1986;48: Ecaterina Usurel et al 267
In some people blood pressure measured in the office is substantially higher
Prevalence and predictors of white-coat response in patients with treated hypertension Mary B. MacDonald,* RN, MCEd; Gail P. Laing,* RN, PhD; Merne P. Wilson, RN, BSN; Thomas W. Wilson, MD A b s t r a
More informationANTIHYPERTENSIVE DRUG THERAPY IN CONSIDERATION OF CIRCADIAN BLOOD PRESSURE VARIATION*
Progress in Clinical Medicine 1 ANTIHYPERTENSIVE DRUG THERAPY IN CONSIDERATION OF CIRCADIAN BLOOD PRESSURE VARIATION* Keishi ABE** Asian Med. J. 44(2): 83 90, 2001 Abstract: J-MUBA was a large-scale clinical
More informationCarlos A. Segre, Rubens K. Ueno, Karim R. J. Warde, Tarso A. D. Accorsi, Márcio H. Miname, Chang K. Chi, Angela M. G. Pierin, Décio Mion Júnior
Original Article White-coat Hypertension and Normotension in the League of Hypertension of the Hospital das Clínicas, FMUSP. Prevalence, Clinical and Demographic Characteristics Carlos A. Segre, Rubens
More informationDoes masked hypertension exist in healthy volunteers and apparently well-controlled hypertensive patients?
O R I G I N A L A R T I C L E Does masked hypertension exist in healthy volunteers and apparently well-controlled hypertensive patients? I. Aksoy, J. Deinum, J.W.M. Lenders, Th. Thien *# Department of
More informationCitation Acta medica Nagasakiensia. 1997, 42
NAOSITE: Nagasaki University's Ac Title Age and Gender Differences in White Author(s) Li, Zhang Ting Citation Acta medica Nagasakiensia. 1997, 42 Issue Date 1997-12-20 URL http://hdl.handle.net/10069/16086
More informationSlide notes: References:
1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory
More informationWhite coat and masked hypertension
White coat and masked hypertension Conflict of interest Support from Spacelabs, Microlife. Honoraria from Novartis, Elpen, Boeringer-Ingelheim, CANA, Lilly, MSD, Sanofi, Menarini, Ciezi, Astra-Zeneca.
More informationEvidence exists indicating that patient adherence to. Frequent Nurse Visits Decrease White Coat Effect in Stage III Hypertension
AJH 2004; 17:523 528 Frequent Nurse Visits Decrease White Coat Effect in Stage III Hypertension Grazia Maria Guerra-Riccio, Dante Marcelo Artigas Giorgi, Fernanda Marciano Consolin-Colombo, José Augusto
More informationAmbulatory blood pressure monitoring has shown that in
Difference Between Clinic and Daytime Blood Pressure Is Not a Measure of the White Coat Effect Gianfranco Parati, Luisa Ulian, Cinzia Santucciu, Stefano Omboni, Giuseppe Mancia Abstract The purpose of
More informationRisk Assessment of developing type 2 diabetes mellitus in patient on antihypertensive medication
41 Research Article Risk Assessment of developing type 2 diabetes mellitus in patient on antihypertensive medication Amarjeet Singh*, Sudeep bhardwaj, Ashutosh aggarwal Department of Pharmacology, Seth
More informationPrognostic significance of blood pressure measured on rising
(2001) 15, 413 417 2001 Nature Publishing Group All rights reserved 0950-9240/01 $15.00 www.nature.com/jhh ORIGINAL ARTICLE Prognostic significance of blood pressure measured on rising P Gosse, C Cipriano,
More informationPrognostic significance of blood pressure measured in the office, at home and during ambulatory monitoring in older patients in general practice
(2005) 19, 801 807 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE Prognostic significance of blood pressure measured in the office, at home and
More informationProtocol. Automated Ambulatory Blood Pressure Monitoring for the Diagnosis of Hypertension in Patients with Elevated Office Blood Pressure
Automated Ambulatory Blood Monitoring for the Diagnosis of Hypertension in Patients with Elevated Office Blood (10102) Medical Benefit Effective Date: 07/01/14 Next Review Date: 03/15 Preauthorization
More informationClinical Significance of Blood Pressure Response Triggered by a Doctor s Visit in Patients with Essential Hypertension
343 Original Article Clinical Significance of Blood Pressure Response Triggered by a Doctor s Visit in Patients with Essential Hypertension Masanori MUNAKATA, Yuki SAITO, Tohru NUNOKAWA, Nobuhiko ITO,
More informationAmbulatory Blood Pressure Monitoring Clinical Practice Recommendations
Acta Medica Marisiensis 2016;62(3):350-355 DOI: 10.1515/amma-2016-0038 UPDATE Ambulatory Blood Pressure Monitoring Clinical Practice Recommendations Mako Katalin *, Ureche Corina, Jeremias Zsuzsanna University
More informationBlood Pressure Control and Quality of Life in Hypertensive Patients Treated with Amlodipine/Valsartan Fixed Dose Combination IMPROVE Study Results
Modern Medicine 2016, Vol. 23, No. 2 ORIGINAL PAPERS Blood Pressure Control and Quality of Life in Hypertensive Patients Treated with Amlodipine/Valsartan Fixed Dose Combination IMPROVE Study Results Oana
More informationand bias, which are known to be present in self-home and in professional office BP measurements taken using the auscultatory technique [7].
Devices and technology 37 Validation of the A&D UM-11 professional hybrid device for office blood pressure measurement according to the International Protocol George S. Stergiou, Periklis P. Giovas, Charilaos
More informationWhat s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
More informationBRIEF COMMUNICATIONS. KEY WORDS: Ambulatory blood pressure monitoring, placebo effect, antihypertensive drug trials.
AJH 1995; 8:311-315 BRIEF COMMUNICATIONS Lack of Placebo Effect on Ambulatory Blood Pressure Giuseppe Mancia, Stefano Omboni, Gianfranco Parati, Antonella Ravogli, Alessandra Villani, and Alberto Zanchetti
More informationORIGINAL ARTICLE AMBULATORY BLOOD PRESSURE IN OBESITY. Introduction. Patients and Methods
Vol. 2, Issue 1, pages 31-36 ORIGINAL ARTICLE AMBULATORY BLOOD PRESSURE IN OBESITY By Alejandro de la Sierra, MD Luis M. Ruilope, MD Hypertension Units, Hospital Clinico, Barcelona & Hospital 12 de Octubre,
More information& Wilkins. a Division of Cardiology, Schulich Heart Centre, b Institute for Clinical and
Original article 333 Optimum frequency of office blood pressure measurement using an automated sphygmomanometer Martin G. Myers a, Miguel Valdivieso a and Alexander Kiss b,c Objective To determine the
More informationCLINICAL SCIENCE. Angela M. G. Pierin a, Edna C. Ignez a, Wilson Jacob Filho b, Alfonso Júlio Guedes Barbato b, Décio Mion Jr. b
CLINICS 2008;63(1):43-50 CLINICAL SCIENCE BLOOD PRESSURE MEASUREMENTS TAKEN BY PATIENTS ARE SIMILAR TO HOME AND AMBULATORY BLOOD PRESSURE MEASUREMENTS Angela M. G. Pierin a, Edna C. Ignez a, Wilson Jacob
More informationClinic blood pressure (BP) is greater than ambulatory or
Attenuation of the White-Coat Effect by Antihypertensive Treatment and Regression of Target Organ Damage Gianfranco Parati, Luisa Ulian, Lorena Sampieri, Paolo Palatini, Alessandra Villani, Alessandro
More informationEchocardiographic definition of left ventricular hypertrophy in the hypertensive: which method of indexation of left ventricular mass?
Journal of Human Hypertension (1999) 13, 505 509 1999 Stockton Press. All rights reserved 0950-9240/99 $12.00 http://www.stockton-press.co.uk/jhh ORIGINAL ARTICLE Echocardiographic definition of left ventricular
More informationAGING, BLOOD PRESSURE & CARDIOVASCULAR DISEASE EVENT RISK. Michael Smolensky, Ph.D. The University of Texas Austin & Houston
AGING, BLOOD PRESSURE & CARDIOVASCULAR DISEASE EVENT RISK Michael Smolensky, Ph.D. The University of Texas Austin & Houston Disclosures Partner: Circadian Ambulatory Diagnostics Consultant: Spot On Sciences
More informationClinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital
Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC
More informationBlood Pressure Targets: Where are We Now?
Blood Pressure Targets: Where are We Now? Diana Cao, PharmD, BCPS-AQ Cardiology Assistant Professor Department of Clinical & Administrative Sciences California Northstate University College of Pharmacy
More informationCopyright Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Devices and technology 261 Validation of the ROSSMAX blood pressure measuring monitor according to the European Society of Hypertension International Protocol for Validation of Blood Pressure Measuring
More informationHypertension Putting the Guidelines into Practice
Hypertension 2017 Putting the Guidelines into Practice Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or
More informationAmbulatory BP Monitoring: Getting the Diagnosis of Hypertension Right. Anthony J. Viera, MD, MPH, FAHA Professor and Chair
Ambulatory BP Monitoring: Getting the Diagnosis of Hypertension Right Anthony J. Viera, MD, MPH, FAHA Professor and Chair Objectives Review limitations of office BP in making a correct diagnosis of hypertension
More informationHypertension Management Controversies in the Elderly Patient
Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No
More informationAmbulatory blood pressure measurement is now indispensable to the good clinical management of hypertension
CARDIOVASCULAR JOURNAL OF SOUTH AFRICA Vol 14, No. 3, May/June 2003 113 Editorial Ambulatory blood pressure measurement is now indispensable to the good clinical management of hypertension Ambulatory blood
More informationORIGINAL INVESTIGATION. Is Isolated Home Hypertension as Opposed to Isolated Office Hypertension a Sign of Greater Cardiovascular Risk?
ORIGINAL INVESTIGATION Is Isolated Home as Opposed to Isolated Office a Sign of Greater Cardiovascular Risk? Guillaume Bobrie, MD; Nathalie Genès, MD; Laurent Vaur, MD; Pierre Clerson, MD; Bernard Vaisse,
More informationAssessing Blood Pressure for Clinical Research: Pearls & Pitfalls
Assessing Blood Pressure for Clinical Research: Pearls & Pitfalls Anthony J. Viera, MD, MPH, FAHA Department of Family Medicine Hypertension Research Program UNC School of Medicine Objectives Review limitations
More informationCARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES
CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES C. Liakos, 1 G. Vyssoulis, 1 E. Karpanou, 2 S-M. Kyvelou, 1 V. Tzamou, 1 A. Michaelides, 1 A. Triantafyllou, 1 P. Spanos, 1 C. Stefanadis
More informationDIURNAL VARIATIONS IN BLOOD PRESSURE AND THEIR RELATION WITH CAROTID ARTERY INTIMA-MEDIA THICKENING
DIURNAL VARIATIONS IN BLOOD PRESSURE AND THEIR RELATION WITH CAROTID ARTERY INTIMA-MEDIA THICKENING Sh Narooei (1), B Soroor (2), F Zaker (3) Abstract INTRODUCTION: Hypertension is a very common cardiovascular
More informationValidation of the SEJOY BP-1307 upper arm blood pressure monitor for home. blood pressure monitoring according to the European Society of Hypertension
Validation of the SEJOY BP-1307 upper arm blood pressure monitor for home blood pressure monitoring according to the European Society of Hypertension International Protocol revision 2010 Short title: Validation
More informationTodd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM
Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM Faculty Disclosure I have no financial interest to disclose No off-label use of medications will be discussed FIFTH ANNUAL SYMPOSIUM Recognize changes between
More informationOBJECTIVES BACKGROUND METHODS RESULTS CONCLUSIONS
Journal of the American College of Cardiology Vol. 38, No. 1, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01325-0 Silent
More informationHigh-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension
(2005) 19, 491 496 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE High-dose monotherapy vs low-dose combination therapy of calcium channel blockers
More informationHow well do office and exercise blood pressures predict sustained hypertension? A Dundee Step Test Study
(2000) 14, 429 433 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh ORIGINAL ARTICLE How well do office and exercise blood pressures predict sustained hypertension?
More informationJournal of the American College of Cardiology Vol. 46, No. 3, by the American College of Cardiology Foundation ISSN /05/$30.
Journal of the American College of Cardiology Vol. 46, No. 3, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.03.070
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationHypertension and Cardiovascular Disease
Hypertension and Cardiovascular Disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
More informationImportance of Ambulatory Blood Pressure Monitoring in Adolescents
Importance of Ambulatory Blood Pressure Monitoring in Adolescents Josep Redon, MD, PhD, FAHA Internal Medicine Hospital Clinico Universitario de Valencia University of Valencia CIBERObn Instituto de Salud
More informationOHTAC Recommendation: Twenty-Four-Hour Ambulatory Blood Pressure Monitoring in Hypertension. Ontario Health Technology Advisory Committee
OHTAC Recommendation: Twenty-Four-Hour Ambulatory Blood Pressure Monitoring in Hypertension Ontario Health Technology Advisory Committee May 2012 Background Hypertension in Canada Hypertension occurs when
More information1. Department of Gynecology and Obstetrics, St. Joseph's Hospital Berlin Tempelhof, Germany
Page 1 of 9 Validation of the TONOPORT VI ambulatory blood pressure monitor, according to the European Society of Hypertension International Protocol revision 2010 Michael Abou-Dakn 1, Cornelius Döhmen
More informationHypertension Putting the Guidelines into Practice
Hypertension 2017 Putting the Guidelines into Practice Disclosures Relationships with commercial interests: Grants/Research Support: Speakers Bureau/Honoraria: Consulting Fees: Data Safety and Monitoring:
More informationUse of ambulatory and home blood pressure (BP) measurements
Long-Term Risk of Mortality Associated With Selective and Combined Elevation in Office, Home, and Ambulatory Blood Pressure Giuseppe Mancia, Rita Facchetti, Michele Bombelli, Guido Grassi, Roberto Sega
More informationPrevalence, awareness of hypertension in rural areas of Kurnool
Original article: Prevalence, awareness of hypertension in rural areas of Kurnool Dr. Sudhakar Babu*, Dr.Aruna MS** *Associate Professor, Dept of Community Medicine, Vishwa Bharathi Medical College Kurnool,
More informationDifferent Metabolic Predictors of White-Coat and Sustained Hypertension Over a 20-Year Follow-Up Period. A Population-Based Study of Elderly Men
Different Metabolic Predictors of and Hypertension Over a 20-Year Follow-Up Period A Population-Based Study of Elderly Men Kristina Björklund, MD; Lars Lind, MD, PhD; Bengt Vessby, MD, PhD; Bertil Andrén,
More informationThe Evolution To Treatment Of Hypertension With Advanced Formulation
The Evolution To Treatment Of Hypertension With Advanced Formulation Dr. Donald Ang MBChB (UK) FRCP (Edin) MD (UK) CCST Cardiology (UK) FESC (Europe) Consultant Cardiologist Island Hospital Penang High
More informationBLOOD PRESSURE MEASUREMENT HOME BASED OR OFFICE BP MONITORING WHICH, HOW AND WHEN?
BLOOD PRESSURE MEASUREMENT HOME BASED OR OFFICE BP MONITORING WHICH, HOW AND WHEN? DECLARATION OF INTEREST Medical Director and Chairman, Advisory Board dabl Ltd., Dublin, Ireland. BLOOD PRESSURE MEASUREMENT
More informationSTATE OF THE ART BP ASSESSMENT
STATE OF THE ART BP ASSESSMENT PROFESSOR MOLECULAR PHARMACOLOGY CONWAY INSTITUE UNIVERSITY COLLEGE DUBLIN CO-CHAIRMAN BLOOD PRESCSURE MANAGEMENT IN LOW RESOURCE SETTINGS CENTRE FOR INTERNATIONAL HUMANITARIAN
More informationALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
More informationClinical Significance and Treatment Requirements in White Coat and Masked Hypertension
Clinical Significance and Treatment Requirements in White Coat and Masked Hypertension 2 Jean-Michel Mallion 2.1 Introduction The phenomena of white coat hypertension (WCHT) and masked hypertension (MH)
More informationPrognostic Value of Different Indices of Blood Pressure Variability in Hypertensive Patients
articles nature publishing group Prognostic Value of Different Indices of Blood Pressure Variability in Hypertensive Patients Sante D. Pierdomenico 1,2, Marta Di Nicola 3, Anna L. Esposito 3, Rocco Di
More informationTHE NEW ARMENIAN MEDICAL JOURNAL DISTRIBUTION, AWARENESS, TREATMENT, AND CONTROL OF ARTERIAL HYPERTENSION IN YEREVAN (ARMENIA)
THE NEW ARMENIAN MEDICAL JOURNAL Vol.5 (2011), Nо 2, p.29-34 DISTRIBUTION, AWARENESS, TREATMENT, AND CONTROL OF ARTERIAL HYPERTENSION IN YEREVAN (ARMENIA) Zelveian P.H. 1, 2, Podosyan G.A. 2 1 Institute
More informationAmbulatory blood pressure (ABP) may be normal in
Response to Antihypertensive Therapy in Older Patients With Sustained and Nonsustained Systolic Hypertension Robert H. Fagard, MD; Jan A. Staessen, MD; Lutgarde Thijs, BSc; Jerzy Gasowski, MD; Christopher
More informationa Hypertension and Cardiovascular Rehabilitation Unit, Faculty of Medicine, Received 2 June 2008 Revised 1 July 2008 Accepted 9 July 2008
Original article 325 Prognostic significance of ambulatory blood pressure in hypertensive patients with history of cardiovascular disease Robert H. Fagard a, Lutgarde Thijs a, Jan A. Staessen a, Denis
More information4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?
HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL
More informationBlood Pressure Targets in Diabetes
Stockholm, 29 th August 2010 ESC Meeting Blood Pressure Targets in Diabetes Peter M Nilsson, MD, PhD Department of Clinical Sciences University Hospital, Malmö Sweden Studies on BP in DM2 ADVANCE RCT (Lancet
More informationSympathetic Neural Mechanisms in White-Coat Hypertension
Journal of the American College of Cardiology Vol. 40, No. 1, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)01931-9
More informationHow do we diagnose hypertension today? Presentation Subtitle
How do we diagnose hypertension today? Presentation Subtitle Renata Cífková Case 1 JM, a 64-year-old lady referred to our center because of undesirable effects of her antihypertensive medication Personal
More informationMasked Hypertension: A Review
479 Review Hypertens Res Vol.30 (2007) No.6 p.479-488 Masked Hypertension: A Review Thomas G. PICKERING 1), Kazuo EGUCHI 1),2), and Kazuomi KARIO 2) Masked hypertension is defined as a normal blood pressure
More informationComparison of manual versus automated blood pressure measurement in intensive care unit, coronary care unit, and emergency room.
Comparison of manual versus automated blood pressure measurement in intensive care unit, coronary care unit, and emergency room Abstract Ahmad Mirdamadi (1), Mostafa Etebari (2) Original Article BACKGROUND:
More informationTHE ACCURATE ASSESSMENT
ORIGINAL INVESTIGATION Consistency of Blood Pressure Differences Between the Left and Right s Kazuo Eguchi, MD; Mona Yacoub, MD; Juhee Jhalani; William Gerin, PhD; Joseph E. Schwartz, PhD; Thomas G. Pickering,
More informationHypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town
Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the
More informationEarly Detection of Damaged Organ
Early Detection of Damaged Organ Regional Cardiovascular Center, Chungbuk National University Kyung-Kuk Hwang Contents NICE guideline 2011 - Confirm the diagnosis of HT ambulatory blood pressure monitoring
More informationNew Hypertension Guideline Recommendations for Adults July 7, :45-9:30am
Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July
More informationHipertensión enmascarada. Alejandro de la Sierra Hospital Mútua Terrassa Universitat de Barcelona
Hipertensión enmascarada Alejandro de la Sierra Hospital Mútua Terrassa Universitat de Barcelona HTA enmascarada Definición Prevalencia Características clínicas Riesgo derivado Asociación con LOD Progresión
More informationORIGINAL INVESTIGATION. Blunted Heart Rate Dip During Sleep and All-Cause Mortality. clinical practice and in hypertension
ORIGINAL INVESTIGATION Blunted Heart Rate Dip During Sleep and All-Cause Mortality Iddo Z. Ben-Dov, MD; Jeremy D. Kark, MD; Drori Ben-Ishay, MD; Judith Mekler, MSc; Liora Ben-Arie; Michael Bursztyn, MD
More informationUpdate on HTN and ABPM. Raj Padwal Division of General Internal Medicine University of Alberta
Update on HTN and ABPM Raj Padwal Division of General Internal Medicine University of Alberta Disclosures Funding: CIHR, AIHS, HSF, UHF Research Collaboration: Novo Nordisk, CVRx Consulting: Vivus, Medtronic
More informationHypertension is a common medical disorder, affecting. Is Resistant Hypertension Really Resistant? Mark A. Brown, Megan L. Buddle, and Allison Martin
AJH 2001; 14:1263 1269 Is Resistant Hypertension Really Resistant? Mark A. Brown, Megan L. Buddle, and Allison Martin Background: Managing resistant hypertension is difficult and mostly involves expensive
More informationGender differences in coronary heart disease in Turkey
Original Article Gender differences in coronary heart disease in Turkey Mehmet Rami Helvaci 1, Hasan Kaya 2, Mehmet Gundogdu 3 ABSTRACT Objectives: To find out whether or not there are some gender differences
More informationLIVER FUNCTION TESTS ANOMALIES IN PATIENTS WITH CHRONIC HEART FAILURE
: 145-149 Original Paper Copyright Celsius LIVER FUNCTION TESTS ANOMALIES IN PATIENTS WITH CHRONIC HEART FAILURE Camelia C. Diaconu 1, Alice Bãlãceanu 2, Daniela Bartoæ 1 1 Carol Davila University of Medicine
More informationMureş, Romania 2 Discipline of Pharmacology, University of Medicine and Pharmacy of
FARMACIA, 2013, Vol, 61, 4 713 THE EFFICIENCY OF METOPROLOL TARTRATE IN THE TREATMENT OF PURE ARTERIAL HYPERTENSION AT PATIENTS WITH CORONARY ARTERY DISEASE AND THE RISK FACTORS ASSOCIATED DANIEL LAURENTIU
More informationCopyright Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Devices and technology 223 Validation of the A&D UA-705 device for self-measurement of blood pressure according to the British Hypertension Society protocol Paolo Verdecchia, Fabio Angeli, Roberto Gattobigio,
More informationThe role of physical training in lowering the cardio-metabolic risk
The role of physical training in lowering the cardio-metabolic risk Timea Szasz 1, Eugen Bota 2, Lucian Hoble 3 Abstract The cardio-metabolic risk represents the overall risk of developing type 2 diabetes
More informationAdult Hypertension Is Associated With Blood Pressure Variability in Childhood in Blacks and Whites: The Bogalusa Heart Study
nature publishing group original contributions Adult Hypertension Is Associated With Blood Pressure Variability in Childhood in Blacks and Whites: The Bogalusa Heart Study Wei Chen 1,2, Sathanur R. Srinivasan
More informationPatrick Kay, General and Interventional Cardiologist Auckland or healthpoint.co.nz
Patrick Kay, General and Interventional Cardiologist Auckland ipatkay@hotmail.com or healthpoint.co.nz Rotorua 2015 Rotorua 2015 Graphical example of true mean and variation, and of regression to the
More informationWhat s the evidence, why do guidelines differ, and what should the GP do?
What s the evidence, why do guidelines differ, and what should the GP do? Richard McManus Barcelona 2018 Overview What is hypertension? How should blood pressure be measured/diagnosed? What should we be
More informationJ-curve Revisited. An Analysis of Blood Pressure and Cardiovascular Events in the Treating to New Targets (TNT) Trial
J-curve Revisited An Analysis of Blood Pressure and Cardiovascular Events in the Treating to New Targets (TNT) Trial Sripal Bangalore, MD, MHA, Franz H Messerli, MD, Chuan-Chuan Wun, PhD, Andrea L. Zuckerman,
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationThe magnitude and duration of ambulatory blood pressure reduction following acute exercise
Journal of Human Hypertension (1999) 13, 361 366 1999 Stockton Press. All rights reserved 0950-9240/99 $12.00 http://www.stockton-press.co.uk/jhh ORIGINAL ARTICLE The magnitude and duration of ambulatory
More informationThe hypertensive effects of the renin-angiotensin
Comparison of Telmisartan vs. Valsartan in the Treatment of Mild to Moderate Hypertension Using Ambulatory Blood Pressure Monitoring George Bakris, MD A prospective, randomized, open-label, blinded end-point
More informationAmbulatory blood pressure measurement (ABPM) is being used increasingly in clinical practice.
Hypertension AMBULATORY BLOOD PRESSURE MONITORING IN THE MANAGEMENT OF HYPERTENSION c WHY Correspondence to: Professor Eoin O Brien, Blood Pressure Unit and ADAPT Centre, Beaumont Hospital, Dublin 9, Ireland;
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationGoing to high altitude with heart disease. Prof. Dr. med. Stefano Rimoldi High Altitude Medicine Inselspital Bern
Going to high altitude with heart disease Prof. Dr. med. Stefano Rimoldi High Altitude Medicine Inselspital Bern stefano.rimoldi@insel.ch There are very few studies on patients with heart disease going
More informationJournal of Hypertension 2004, 22: a Hypertension and Cardiovascular Rehabilitation Unit, Catholic University of
Original article 81 Relationship between ambulatory blood pressure and followup clinic blood pressure in elderly patients with systolic hypertension Robert H. Fagard a, Jan A. Staessen a, Lutgarde Thijs
More informationFOR many years, casual blood pressure (BP)
What Is the Value of Home Blood Pressure Measurement in Patients with Mild Hypertension? HOLLIS D. KLEINERT, GREGORY A. HARSHFIELD, THOMAS G. PICKERING, RICHARD B. DEVEREUX, PATRICIA A. SULLIVAN, ROSE
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationUsing Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly
Using Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly Paul Muntner, PhD MHS Professor and Vice Chair Department of Epidemiology University of Alabama
More informationMETHODS. Shachaf Shiber-Ofer, MD; 1,2 Zipora Shohat, MSc; 3,2 Alon Grossman, MD 4,2
ORIGINAL PAPER Elevated Diastolic, But Not Systolic, Blood Pressure Measured in the Emergency Department Predicts Future Development of Hypertension in Normotensive Individuals Shachaf Shiber-Ofer, MD;
More informationCopyright Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Devices and technology 57 Comparison of wrist-type and arm-type 24-h blood pressure monitoring devices for ambulatory use Takahiro Komori a, Kazuo Eguchi a, Satoshi Hoshide a, Bryan Williams b and Kazuomi
More informationORIGINAL INVESTIGATION. Pharmacist-Physician Comanagement of Hypertension and Reduction in 24-Hour Ambulatory Blood Pressures
ORIGINAL INVESTIGATION Pharmacist-Physician Comanagement of Hypertension and Reduction in 24-Hour Ambulatory Blood Pressures Cynthia A. Weber, PharmD; Michael E. Ernst, PharmD; Genesis S. Sezate, BS; Shimin
More informationHOW CONSISTENT ARE THE BLOOD PRESSURE AND PULSE RATE MEASUREMENTS OF THE ELECTRONIC BP APPARATUS AND THE MANUAL SPHYGMOMANOMETER
HOW CONSISTENT ARE THE BLOOD PRESSURE AND PULSE RATE MEASUREMENTS OF THE ELECTRONIC BP APPARATUS AND THE MANUAL SPHYGMOMANOMETER Naser KA. Teaching Hospital Peradeniya, Peradeniya, Sri Lanka Zawahir S
More informationUniversity of Padova, Padua, Italy, and HARVEST Study Group, Italy
University of Padova, Padua, Italy, and HARVEST Study Group, Italy ISOLATED SYSTOLIC HYPERTENSION IN THE YOUNG DOES NOT IMPLY AN INCREASED RISK OF FUTURE HYPERTENSION NEEDING TREATMENT Mos L, Saladini
More informationHypertension and the SPRINT Trial: Is Lower Better
Hypertension and the SPRINT Trial: Is Lower Better 8th Annual Orange County Symposium on Cardiovascular Disease Prevention Saturday, October 8, 2016 Keith C. Norris, MD, PhD, FASN Professor of Medicine,
More information